Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
While a mere 8% of patients undergoing clinical monitoring experienced improvements in their depressive symptoms, significant improvement was noted in 56% of those engaged in cognitive-behavioral therapy
Where semaglutide, a GLP-1-only agonist, produces roughly 15% body weight loss on average, tirzepatide pushes past 20%
Alternatively, those in the placebo group maintained only 49.2% of their prior weight loss, resulting in a treatment difference of around 25.5% weight reduction
that kickstarted the widespread adoption of weight-loss medications
however, further investigations are warranted
The market is expected to grow from $43,904 million in 2025 at a compound annual growth rate (CAGR) of 13%
US$ 20.43
US$ 26.04
US$ 26.55
US$ 23.59
US$ 24.46
US$ 24.62
